Combination treatments with CTLA4 and PD-1 blockers have been approved as the first line therapy for advanced melanoma patients and are being tested in other tumor types with different dose levels and intervals of anti-CTLA4 to reduce toxicity. Here, CTLA4 is linked to melanoma.